A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Recruiting · Phase 2 · NCT07015242
Conditions: Lymphoma
At a glance
- Research payments reported, 2025
- $3,479
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Tested
- Rituximab (drug), Methotrexate (drug), Procarbazine (drug), Temozolomide (drug), Liso-cel (biological), Fludarabine (drug), Cyclophosphamide (drug), Calcium folinate (drug)
- Dates
- Started 2025-11-06; completion 2028-12-10
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $3,479 in research payments for this study in 2025 (2 payments).
Products named: Breyanzi, Rituxan
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael D. Jain, MD Hematology · Tampa, FL
- Allison M. Winter, M.D. Hematology & Oncology · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Moffitt Cancer Center $2,770
- Cleveland Clinic $709
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.